Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial

Turn

Turn

TTRX

0.00
  • Turn Therapeutics released interim Phase 2 results for topical GX-03 in adults with moderate-to-severe atopic dermatitis.
  • The analysis showed faster, more substantial symptom improvement versus vehicle, with benefits deepening over the treatment period.
  • Safety looked favorable, with no treatment-related serious adverse events or treatment-related discontinuations reported in the interim cohort.
  • The readout prompted changes to enrollment criteria and endpoint priorities to sharpen the second stage of the ongoing trial.
  • More detailed findings will be presented at the Jefferies Global Healthcare conference on June 4, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606010830BIZWIRE_USPR_____20260601_BW276401) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.